Date of submission of the HTAC Recommendation: 20 July 2026
Date of notification to HTAC on the SOH decision: 26 August 2026

The Secretary of Health (SOH) concurs with the final recommendation of the HTA Council on levothyroxine sodium 12.5 micrograms (mcg) and 25 mcg tablets for the management of hypothyroidism of any etiology through Department of Health (DOH) Department Circular No. 2026-0461 “Inclusion of Additional Dosage Strengths of Levothyroxine in the Philippine National Drug Formulary (PNDF)” dated 27 July 2026. 

As a final recommendation, the HTA Council recommends the government financing of levothyroxine sodium 12.5 mcg and 25 mcg tablets. However, due to the substantial budget impact of financing these drugs, the DOH should strongly consider conducting price negotiations to ensure affordability and sustainable access to these treatments.

For further details, please refer to the documents below: